<?xml version="1.0" encoding="UTF-8"?>
<p id="p0250">Scientists reported in one study how the spike-like glycoprotein of the SARS-CoV-2 virus binds to the ACE2 receptor. Accordingly, the presence of transmembrane protease serine2 (TMPRSS 2) is required for spike protein priming. The researchers found that Camostat mesylate
 <italic>,</italic> a serine protease inhibitor, could block the entry of SARS-CoV-2 into lung cells. So, it might be effective against COVID-19. However the application of this drug as a treatment for COVID-19 requires clinical trials 
 <xref rid="b0475" ref-type="bibr">[95]</xref>.
</p>
